The First AI Legally Authorized to Practice Medicine Just Raised $40M

A New York-based startup that became the first AI system to legally renew prescriptions in the United States has closed a $40 million Series B round, signaling that the era of autonomous clinical AI is no longer hypothetical—it's here, and investors are piling in.

Doctronic announced the raise on March 24, 2026, with Abstract and Lightspeed Venture Partners co-leading the round. Existing investors Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures also participated, bringing total funding to over $65 million—all raised in less than a year across three rounds. The velocity alone tells a story: this is a company that's growing faster than most healthcare startups dare to dream.

From Surgeon and Engineer to AI Healthcare Pioneer

Doctronic was founded in 2023 by an unusual pairing. Dr. Adam Oskowitz is a practicing vascular surgeon at UCSF and an Associate Professor with over two decades of experience at top medical institutions and a deep publication record. Matt Pavelle is a serial entrepreneur with 25 years of startup experience, a Carnegie Mellon CS graduate, and the former founding CTO of luxury fashion unicorn Moda Operandi. Pavelle also comes from a family of medical professionals—a background that shaped his conviction that healthcare delivery was fundamentally broken.

Together, they built a platform that goes far beyond the chatbot paradigm. Doctronic operates its own clinical practice, licensed in all 50 states, HIPAA-compliant, and available around the clock. The service launched with human clinicians in January 2025, and has since evolved into what the company calls "the world's most popular AI doctor."

Under the Hood: 100+ AI Agents Working in Concert

What sets Doctronic apart technically is its multi-agent architecture—over 100 specialized AI components, each handling specific clinical tasks. These agents communicate dynamically, passing information to build a comprehensive picture of each patient's condition. Think of it as a virtual medical team rather than a single AI model.

The platform leverages proprietary Retrieval-Augmented Generation (RAG) technology backed by a custom medical knowledge graph containing thousands of clinical guidelines, treatment protocols, and evidence-based recommendations. Data integrations run deep: patient records via QHIN/TEFCA, medication history through Surescripts, and drug interaction screening through First Databank.

The clinical performance numbers are striking. In a 500-patient study across urgent care settings, Doctronic achieved 99.2% treatment plan consistency with board-certified physicians, with zero hallucinations. In discordant cases, the AI was 4x more accurate than physicians—a remarkable claim that suggests the system may actually exceed human clinical judgment in certain scenarios. For context, general-purpose LLMs like ChatGPT typically achieve only 50-55% accuracy in comparable clinical assessments.

The Utah Breakthrough: AI Writes Its Own Prescriptions

The headline milestone came in December 2025, when Doctronic became the first AI-native platform to autonomously renew prescriptions under Utah's AI Learning Lab regulatory sandbox. This wasn't a human-in-the-loop arrangement—the AI independently evaluated patients and renewed prescriptions for 190 medications, with automatic escalation to licensed physicians for complex cases.

This is a watershed moment for healthcare AI. While hundreds of AI tools have received FDA clearance for diagnostic imaging and clinical decision support, none have crossed the threshold into autonomous prescriptive authority. Doctronic did it first, and the regulatory precedent could open doors for similar programs nationwide.

The company is now preparing for its first formal FDA meeting, a critical next step toward federal-level regulatory validation of autonomous clinical AI.

Growth Metrics That Caught Investors' Attention

The numbers since the Series A tell a compelling story of product-market fit:

• 15x revenue growth since closing the Series A, reaching 8-figure annualized revenue (projected to exceed $10M)
• Repeat patient rate nearly tripled
• Over 300,000 unique weekly visitors
• 15 million cumulative AI consultations
• Over 1 million unique patients served globally

These aren't vanity metrics. The repeat patient rate is particularly meaningful—it suggests the AI is delivering clinical value that brings patients back, not just curiosity-driven one-time visits. The $39-per-interaction price point positions Doctronic well below traditional telehealth services while maintaining strong unit economics at scale.

Market Context: Healthcare AI's Hottest Sector

Doctronic is riding multiple converging tailwinds. The global healthcare AI market stands at approximately $52 billion in 2026, projected to reach $1.2 trillion by 2035. The more specific AI-powered clinical decision support market is valued at $857 million and growing at a 15.4% CAGR toward $2.3 billion by 2032.

AI now represents 46% of all healthcare venture investment, and according to J.P. Morgan, 75% of health tech funding flows to AI-focused companies. The average Series B-D round for healthcare AI startups is $26.1 million—making Doctronic's $40M raise a clear signal of outsized investor confidence.

The competitive landscape is heating up. Hippocratic AI raised $141 million at a $1.64 billion valuation for healthcare-specific AI agents. Qualified Health just closed a $125 million Series B in March 2026 for hospital AI management tools. At the federal level, ARPA-H's ADVOCATE program is working to develop the first FDA-authorized agentic AI for cardiovascular care, with team selection expected in June 2026.

But Doctronic occupies a unique niche. While competitors focus on workflow automation, staffing solutions, or diagnostic imaging, Doctronic is the only company that has achieved autonomous prescriptive authority—the ability for AI to independently make and execute clinical decisions with legal backing.

What the Money Will Fund

The Series B capital will be deployed across four strategic priorities:

• Hospital and academic partnerships: Expanding B2B distribution channels to embed Doctronic's technology within existing healthcare systems
• Digital health and payer integrations: Building connections with insurance companies and telehealth platforms
• Pediatrics expansion: A high-demand, underserved market where consumer need far outpaces physician supply
• Rapid hiring: Scaling the team to support what the company describes as "explosive growth"

The pediatrics play is strategically astute. Parents of young children represent one of the highest-demand segments for immediate medical consultation, and pediatrician shortages are acute across the U.S. A 24/7 AI doctor that can triage, consult, and in some cases prescribe could be transformative for millions of families.

Why Investors Bet Big

Lightspeed, which led the Series A and doubled down on the Series B, outlined three core investment theses in a published analysis: the multi-agent AI architecture provides a technical moat; the centralized health data accumulation creates a compounding advantage; and the HIPAA-compliant infrastructure built from day one positions the company ahead of retrofitted competitors.

The structural thesis is equally compelling. Over 100 million Americans lack easy access to primary care, average wait times exceed one month, and the U.S. faces a projected shortfall of 44,000 family medicine physicians by 2037. Doctronic isn't just a technology bet—it's a bet that autonomous AI will become a structural necessity in American healthcare delivery.

What to Watch

Doctronic sits at the most consequential intersection in healthcare AI: where technology capability meets regulatory willingness. The upcoming FDA meeting could set the template for how the federal government approaches autonomous clinical AI. Whether the Utah prescription model expands to other states, how hospital system partnerships develop, and whether the company can maintain its clinical accuracy at massive scale will be the defining questions of the next 12 months. In a market that's long talked about AI replacing doctors, Doctronic is the first company that's actually, legally, doing it.

---

Sources:

• BusinessWire: Doctronic Raises $40M Series B
• STAT News: AI doctor startup Doctronic raises $40 million
• Lightspeed: Investing in Doctronic
• MobiHealthNews: AI doctor startup Doctronic garners $40M
• Axios: Doctronic raises $40M for AI-enabled telemedicine
• HLTH: AI Doctor Startup Doctronic Garners $40M
• Fierce Healthcare: Trump administration creating clinical AI agents